Janux Therapeutics (JANX) said late Wednesday it priced a public offering of 5.3 million shares at $63 per share, along with pre-funded warrants for 238,095 shares at $62.999 per warrant.
The offering is expected to raise approximately $350 million in gross proceeds. The underwriters have a 30-day option to purchase up to 833,333 additional shares.
Proceeds from the offering, set to close on Friday, will support the clinical development of the company's product pipeline and general corporate purposes, Janux said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.